Toverifytheanti-tumoureffectsofpolyscaccharideisolatedfromTangerineskinonmicetransplantabletumour,andtodevelopanewanticancerdrugfromplant.MiceweretransplantedwithS-180sarcomaorEhrhch'sasciticcarcinomaandhumanhysterotrachecarcinomaHelaceli.Drugsweregivendaily,byoraladministration.Forsevendays,ontheeighthdayanimalsweresacrificed.Peripheralbloodcellcounts,aswellasplasmasupemxidedismutase(SOD),malondialdehyde(MDA)andredbloodcellimmunityfunctiondetermination.TheinhibitionrateofTangerineskinpolysaccharideformiceS-180andEACwere21.6%and27.3%respectively.'FneeffecttoHealcellweredeteminedbyMTT.TheeffectofTangerineskinpolysccharideonperipheralbloodcountswereincreasednumbersofperipheralleukocytesandlymphocytes,theTangerineskinpolysaccharidegroupwashigherthanAnliurugroup(P<0.01).PlasmSODactivitywereincreased,MDAcontentdepressed,butnodifference.Redbloodceilimmunefunctionincreased(P<0.01).TheinhibitionrateforhumanhysterotrachecarcinomaHelaceilwere52.4%,63.0%and72.0%.Tangerineskinpolysaccharideexhibitedanti-canceractivityandmayincreaseperipheralleucocytecountandnumberoflymphocytesandenhanceimmunompetece.Itispromisinginadjuvanttherapy.Furtherstudyisworthcontinuing.
